Interesting CERS Put And Call Options For August 2015
at The Street - Wed Dec 24, 11:43AM CST
Investors in Cerus Corp. saw new options become available this week, for the August 2015 expiration.
CERS: 6.49 (+0.29)
Today's Dead Cat Bounce Stock Is Cerus (CERS)
at The Street - Wed Dec 24, 9:02AM CST
Trade-Ideas LLC identified Cerus (CERS) as a "dead cat bounce" (down big yesterday but up big today) candidate
CERS: 6.49 (+0.29)
Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Business Wire - Mon Dec 22, 7:30AM CST
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated red blood cells continued to circulate 24 hours following transfusion. The investigators plan to submit data from the study for presentation at an upcoming scientific congress.
CERS: 6.49 (+0.29)
Cerus Soaring On FDA Approval Of Intercept
Value Insight - at Seeking Alpha - Fri Dec 19, 7:47PM CST
CERS: 6.49 (+0.29), BAX: 74.45 (-0.04)
FDA clears expanded label for Cerus Intercept Blood System
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:13AM CST
CERS: 6.49 (+0.29)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST
KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)
FDA Approves INTERCEPT Blood System for Platelets
Business Wire - Thu Dec 18, 6:20PM CST
Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for platelets. The INTERCEPT platelet system is approved for ex vivo preparation of pathogen-reduced apheresis platelet components in order to reduce the risk of transfusion-transmitted infection (TTI), including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).
CERS: 6.49 (+0.29)
Nasdaq stocks posting largest percentage increases
AP - Thu Dec 18, 12:48PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
CERS: 6.49 (+0.29), PTRY: 36.78 (+0.28), DRIV: 24.49 (+0.09), MTLS: 9.12 (-0.08), VOLC: 17.95 (+0.02), NPSP: 35.06 (+1.18), NYNY: 7.89 (+0.32), XNCR: 16.83 (+0.77), AREX: 6.98 (-0.11)
Cerus Up 44.4% Since SmarTrend Uptrend Call (CERS)
Comtex SmarTrend(R) - Thu Dec 18, 9:15AM CST
SmarTrend identified an Uptrend for Cerus (NASDAQ:CERS) on October 16th, 2014 at $4.23. In approximately 2 months, Cerus has returned 44.38% as of today's recent price of $6.10.
CERS: 6.49 (+0.29)
Strength Seen in Cerus (CERS): Stock Soars 22.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 8:25AM CST
Cerus (CERS) was a big mover last session, with shares rising roughly 23% on the day.
CERS: 6.49 (+0.29), ICUI: 83.38 (+1.63)
MGM Resorts and FedEx are big market movers
AP - Wed Dec 17, 3:26PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
CERS: 6.49 (+0.29), DRIV: 24.49 (+0.09), FDX: 176.42 (-0.52), RT: 6.30 (+0.10), VOLC: 17.95 (+0.02), ASPX: 49.93 (-0.10), MSFT: 48.14 (-0.31), MGM: 20.77 (-0.17), XL: 34.26 (-0.11)
Stocks in the News: Analyst Coverage on Encana, Unisys, Salix, Cerus and Eli Lilly
PR Newswire - Wed Dec 17, 8:20AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Encana (NYSE: ECA), Unisys (NYSE: UIS), Salix (NASDAQ: SLXP), Cerus (NASDAQ: CERS), and Eli Lilly (NYSE: LLY). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CERS: 6.49 (+0.29), ECA: 13.73 (-0.03), SLXP: 114.92 (-1.18), UIS: 29.77 (-0.43), LLY: 70.16 (+0.42)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:13AM CST
CERS: 6.49 (+0.29), FRO: 2.43 (-0.01), KNDI: 12.90 (+0.99), GFI: 4.37 (+0.13), CLF: 6.06 (-0.09), NVGN: 2.40 (-0.09), ASPX: 49.93 (-0.10), DRIV: 24.49 (+0.09), SID: 2.24 (-0.08), HALO: 9.34 (+0.31), VOLC: 17.95 (+0.02), POZN: 7.86 (+0.07), ICLD: 3.00 (-0.02), TASR: 26.86 (+0.84), DGLY: 15.62 (+0.82), SBGL: 7.13 (+0.20)
Cerus set for gap up at the open after Intercept approval
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 7:01AM CST
CERS: 6.49 (+0.29)
Cerus +20.3% AH; FDA approves Intercept for plasma
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 6:21PM CST
CERS: 6.49 (+0.29)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 4:42PM CST
NGL: 28.65 (-0.49), CERS: 6.49 (+0.29), MEG: 17.13 (-0.34), UWTI: 13.91 (-0.27), IAG: 2.41 (+0.06), CLF: 6.06 (-0.09), EWM: 13.45 (+0.06), EPAM: 48.84 (+0.33), CLNE: 5.25 (-0.15), ARO: 2.30 (-0.03)
FDA Approves INTERCEPT Blood System for Plasma
Business Wire - Tue Dec 16, 4:31PM CST
Cerus Corporation (NASDAQ: CERS) today announced that the U.S. Food and Drug Administration (FDA) has approved the INTERCEPT Blood System for plasma. The INTERCEPT plasma system is approved for ex vivo preparation of plasma in order to reduce the risk of transfusion-transmitted infection (TTI) when treating patients requiring therapeutic plasma transfusion.
CERS: 6.49 (+0.29)
Hot Stock: Cerus, Shares Gain 6.7% (CERS)
Comtex SmarTrend(R) - Fri Dec 12, 11:36AM CST
Cerus (NASDAQ:CERS) is one of today's best performing low-priced stocks, up 6.7% to $4.91 on 1.1x average daily volume. Thus far today, Cerus has traded 1.1 million shares, vs. average volume of 1.0 million shares per day. The stock has outperformed the Dow (6.7% to the Dow's -1.0%) and outperformed the S&P 500 (6.7% to the S&P's -0.7%) during today's trading.
CERS: 6.49 (+0.29)
Health Care Equipment and Supplies Equities Scrutiny - Abbott Laboratories, Zimmer Holdings, Varian Medical Systems, Edwards Lifesciences, and Cerus
PR Newswire - Thu Dec 11, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), Varian Medical Systems Inc. (NYSE: VAR), Edwards Lifesciences Corporation (NYSE: EW), and Cerus Corporation (NASDAQ: CERS). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, December 10, 2014, ended on a negative note as the Dow Jones Industrial Average finished at 17,533.15, down 1.51% and the NASDAQ Composite closed at 4,684.03, down 1.73%. The S&P 500 finished the session 1.64% lower at 2,026.14. During the trading session, all the ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 803.98, down 1.59%, whereas the index has advanced 8.03% in the previous three months. Register for your complimentary reports on these five stocks at:
CERS: 6.49 (+0.29), ZMH: 114.11 (+0.64), ABT: 45.70 (-0.02), VAR: 88.44 (+0.69), EW: 130.75 (+1.17)